Posted in | Nanomedicine | Nanobusiness

Novartis Receives Licenses for Developing Nanobodies

Ablynx [Euronext Brussels: ABLX] announced today that Novartis has obtained licenses to further develop and commercialise Nanobodies against two complex targets. This has triggered a total of EUR1 million in upfront fees and license payments to Ablynx.

The two targets were the subject of programmes as part of the research agreement between the parties, entered into in 2005 and extended by mutual agreement last year. Novartis will now assume responsibility for the continued progress of both programmes and Ablynx will be eligible to receive development based milestone payments and royalties on sales following commercialisation of the products.

Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "We are excited to see these two complex programmes progressing towards the clinic in Novartis' hands and pleased that the commercial licenses have been executed. The targets are ones where conventional antibody approaches have had limited success. This is further validation of the unique nature of Ablynx's Nanobody platform, where functional Nanobodies have been successfully generated against GPCRs and ion channels. Earlier this year, we announced that we have selected a new GPCR targeting development candidate, ALX-0651, an anti-CXCR4 Nanobody which is being developed by Ablynx."



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Ablynx Nv.. (2019, March 19). Novartis Receives Licenses for Developing Nanobodies. AZoNano. Retrieved on July 13, 2020 from

  • MLA

    Ablynx Nv.. "Novartis Receives Licenses for Developing Nanobodies". AZoNano. 13 July 2020. <>.

  • Chicago

    Ablynx Nv.. "Novartis Receives Licenses for Developing Nanobodies". AZoNano. (accessed July 13, 2020).

  • Harvard

    Ablynx Nv.. 2019. Novartis Receives Licenses for Developing Nanobodies. AZoNano, viewed 13 July 2020,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback